ClinicalTrials.gg
CompletedNCT03627195Updated May 8, 2020Results posted

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

A Phase 1 interventional study of DSP-1349M and placebo in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-05-08.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
28th of 39
40 · median 149
Started
2018
with 2 others
Phase 1
9 of 39
none open now
Registered
36th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 28th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 1, and was the 36th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia

Read the detailed description

This is a single-center, randomized, double-blind, placebo-controlled, inpatient, single ascending dose (SAD) study designed to evaluate the safety, tolerability, and PK of lurasidone injectable suspension in subjects with schizophrenia. This study will determine the minimum intolerable dose (MID), the maximum tolerated dose (MTD) of lurasidone injectable suspension, and characterize the PK profiles of lurasidone and its metabolites in serum (ID-14283, ID-14326, ID-11614, ID-20219, and ID-20220) and urine (ID-14283, ID-14326, and ID-11614) in this subject population. The potential effects of gender on the PK of lurasidone injectable suspension and its metabolites will also be evaluated when applicable.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Subject has capacity; is willing and able to provide written consent for use and disclosure of protected health information per requirements of 45CFR164.508 (Health Insurance Portability and Accountability Act; HIPAA) prior to initiating any study procedure after being informed of the nature of the study, in the opinion of the study staff and PI.

      1. Subject is male or female 18 to 65 years of age, inclusive. 3. Subject has a diagnosis of schizophrenia as per criteria, which in the opinion of the Investigator has been clinically stable for the past 6 months.
      1. Subject has a (BMI) greater than or equal to 19.5 and less than or equal to 38 kg/m2.
      1. Subject does not have abnormal laboratory values per Investigator discretion.
      1. Subject does not have clinically relevant findings from vital signs measurements per Investigator discretion.
      1. Female subject is eligible to enter and participate in the study if she is of:

      a. Non- (ie, physiologically incapable of becoming pregnant, including any female who is pre-menarchal or );

  • Postmenopausal females defined as being amenorrheic for greater than 2 years (or confirmed by FSH level) with an appropriate clinical profile.
  • Women who have not been confirmed as postmenopausal should be advised to use as outlined below.
  • Women who have had a hysterectomy, bilateral oophorectomy or bilateral salpingectomy (as determined by subject's medical history).

    b. Child-bearing potential (all females ≤ 65 years of age), has a negative pregnancy test at screening and agrees to satisfy one of the following requirements:

  • Complete abstinence from intercourse (as part of an abstinent lifestyle) a minimum of 2 months prior to administration of the first dose of study drug, throughout the Treatment Period, and for a minimum of 3 months after completion or premature discontinuation from the study drug; or,
  • Established use of highly effective methods of contraception from 1 month prior to administration of the first dose of study drug, during the Treatment Period, and 60 days after completion or premature discontinuation from the study drug.

    • Because of the unacceptable failure rate of barrier (chemical and/or physical) methods, the barrier method of contraception must only be used in combination with a highly effective method. Post-coital methods of contraception are not permitted.

      1. Male subjects with partners of child bearing potential must be practicing abstinence, part of an abstinent life style or using protocol-specified methods of birth control throughout the study and for 30 days after completion or premature discontinuation from the study drug.
      1. Subject is able and willing to remain off of prior antipsychotic medication until the protocol-specified restabilization period.
      1. Subject has a stable living arrangement for at least 3 months prior to Day -12 and agrees to return to a similar living arrangement after discharge. Such subjects remain eligible to participate in this protocol with approval from the PI. Chronically homeless subjects should not be enrolled. The Medical Monitor should be consulted for individual cases as

Exclusion criteria

Exclusion Criteria:

  1. Subject had an acute exacerbation of psychiatric symptoms requiring change in antipsychotic medication (with reference to drug or dose) within 3 months (90 days) before screening.
  2. Subject has known or suspected carcinoma.
  3. Subject has known presence or history of renal or hepatic insufficiency.
  4. Subject has significant disease(s) or finding(s) on physical examination determined by the Investigator to pose a health concern to the subject while on study.
  5. Subject has a history or presence of clinically significant abnormal (based on ECG central overread report) that may jeopardize the subject's safety to participate in this study, or a screening 12-lead ECG demonstrating any one of the following: heart rate (HR) > 100 bpm, QRS > 120 msec, > 450 msec, or PR > 220 msec.
  6. Subject has known history of a severe reaction to a previous antipsychotic (in the Investigator's opinion), including up to 80 mg/day of oral lurasidone.
  7. Subject has a history of drug-dependence as per criteria during the six month period immediately prior to study entry.
  8. Subject has known or suspected excessive alcohol consumption, (exceeding more than 4 drinks on any single day or more than 14 drinks per week; 1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of the screening visit or a positive urine alcohol test at screening.
  9. Subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the C-SSRS at screening (in the past 1 month [30 days]) or at any point prior to randomization or history of suicidal behavior within the last two years.
  10. Subject has significant orthostatic hypotension at screening (ie, a drop in systolic blood pressure of 30 mmHg or more and/or drop in diastolic blood pressure of 20 mmHg or more on standing).
  11. Subject has presence or history (within the last year) of a medical or surgical condition that might interfere with the absorption, metabolism, or excretion of administered Lurasidone injectable suspension.
  12. Subject has a history of epilepsy or risk of having seizures.
  13. Subject has a positive urine alcohol at screening or on Day -12.
  14. Subject has positive test results within 28 days prior to the start of the study for:

    1. (HIV).
    2. surface antigen and antibody.
    3. Urine drug test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines, methadone, or other drugs of abuse). However, a positive test for benzodiazepines may not result in exclusion of subjects if the Investigator determines that the use of a prescription benzodiazepine is appropriate.
    4. Serum β-human chorionic gonadotropin (HCG) consistent with pregnancy (females only).
  15. Subject has used of any inhibitor or inducer of taken within 28 days prior to drug administration and until discharge.
  16. Subject has have used of concomitant medications that prolong the QT/QTc interval within 28 days prior to Day -12 through follow-up.
  17. Subject has received depot neuroleptics unless the last injection was at least one treatment cycle before Day -12.
  18. Subject has poor peripheral venous access or does not tolerate venipuncture that would cause difficulty for collecting blood samples.
  19. Subject has experienced significant blood loss (≥ 473 mL) or donated blood within 30 days prior to screening, or intends to donate plasma or blood or undergo elective surgery during study participation or within 30 days after the last study visit.
  20. Subject has a prolactin concentration greater than or equal to 200 ng/mL at screening.
  21. Subject is unwilling to abstain from vigorous exercise from Day -12 until study discharge.
  22. Subjects has a significant risk of violent behavior or a significant risk of suicidal behavior based on history or in the PI's judgment OR is considered by the Investigator to be at imminent risk of suicide or injury to self, others, or property.
  23. Subject has a history of allergic reaction (clinically relevant history of drug ) or has a known or suspected sensitivity to any substance that is contained in the study drug or to Polysorbate 80, sodium chloride, or sodium phosphate.
  24. Subject requires treatment with a drug that consistently prolongs the QTc interval.
  25. Subject is currently participating, or has participated in a study with an or marketed compound or device within 30 days prior to signing the , or Protocol D1052024, Version 2.00 Lurasidone Injectable Suspension Confidential and Proprietary 36 13 June 2018 has participated in 3 or more studies within 18 months prior to signing the informed consent.
  26. Subject is a staff member or the relative of a staff member.
  27. Subject, in the Investigator's opinion, is unsuitable in any other way to participate in the study.
  28. Subject is unable or unwilling to comply with study instructions, procedures or restrictions.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    DSP-1349M

    Lurasidone injection suspension (30 mg, 75 mg, 150 mg, 300 mg, and 450 mg)

    Drug: DSP-1349M

  • Placebo comparator
    Placbo

    placebo injection

    Drug: placebo

Interventions

  • DSP-1349M injectable

    Also known as: lurasidone

  • Drugplacebo

    placebo injection

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation

    Number of subjects with any Adverse Events (AEs), serious adverse events (SAEs), and Adverse Events (AEs ) leading to study discontinuation

    Time frame: Day 61

  2. Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration

    The maximum Serum Concentration \[Cmax\] for lurasidone after lurasidone injectable suspension administration

    Time frame: Day 61

  3. Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration

    The area Under the Curve from time 0 to time of last quantifiable concentration \[AUC0-last\] for lurasidone after lurasidone injectable suspension administration

    Time frame: Day 61

07

Results

Posted May 8, 2020

Participant flow

Participant flow — Overall Study
MilestoneLurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlacebo
Started6666610
Completed5666610
Not completed100000
Withdrew: Other (lack of efficacy)100000

Outcome measures

PrimaryIncidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation

Number of subjects with any Adverse Events (AEs), serious adverse events (SAEs), and Adverse Events (AEs ) leading to study discontinuation

Time frame:
Day 61
Reported as:
Number · count of participants
Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation
count of participantsLurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlacebo
Incidence of AEs442455
Incidence of SAEs000000
Incidence of AEs leading to study discontinuation000000
PrimaryMaximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration

The maximum Serum Concentration \[Cmax\] for lurasidone after lurasidone injectable suspension administration

Time frame:
Day 61
Reported as:
Geometric mean · ng/mL
Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration
ng/mLLurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlacebo
Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration1.08 ± 65.63.90 ± 51.65.08 ± 46.58.85 ± 62.89.50 ± 48.30 ± 0
PrimaryArea Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration

The area Under the Curve from time 0 to time of last quantifiable concentration \[AUC0-last\] for lurasidone after lurasidone injectable suspension administration

Time frame:
Day 61
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration
ng*h/mLLurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlacebo
Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration628 ± 54.72000 ± 6.63540 ± 26.04910 ± 47.97490 ± 32.60 ± 0

Adverse events

Collected over 61 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 30 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Lurasidone 75 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Lurasidone 150 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Lurasidone 300 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Lurasidone 450 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Placebo0/10 (0%)0/10 (0%)5/10 (50%)
Most frequent other events
Showing 10 of 50
Most frequent other events
EventLurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlacebo
HeadacheNervous system disorders1/60/60/60/64/61/10
Injection site reactionGeneral disorders0/60/61/62/63/61/10
Skin abrasionInjury, poisoning and procedural complications0/62/60/60/60/60/10
Weight increasedInvestigations0/60/62/60/61/62/10
SomnolenceNervous system disorders0/61/61/60/60/62/10
Ear painEar and labyrinth disorders0/60/60/60/61/60/10
Vision blurredEye disorders1/60/60/60/60/60/10
Abdominal pain lowerGastrointestinal disorders1/60/60/60/60/60/10
ConstipationGastrointestinal disorders1/60/60/60/61/61/10
DiarrhoeaGastrointestinal disorders0/60/60/60/61/60/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlaceboTotal
<=18 years0000000
Between 18 and 65 years666661040
>=65 years0000000
Age, Continuous
Age, Continuous(Years)Lurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlaceboTotal
Mean43.7 ± 13.2945 ± 10.2252 ± 4.4746.2 ± 9.7252.8 ± 11.8145.7 ± 10.2547.4 ± 10.23
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlaceboTotal
Female32221515
Male34445525
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlaceboTotal
Hispanic or Latino1102026
Not Hispanic or Latino55646834
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlaceboTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0001001
Black or African American54544729
White12112310
More than one race0000000
Unknown or Not Reported0000000
Height (cm)
Height (cm)(cm)Lurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlaceboTotal
Mean170 ± 8.83173.2 ± 8.61174.3 ± 10.39166.3 ± 7.92174.2 ± 7.25168.5 ± 7.07170.8 ± 8.29
Weight (kg)
Weight (kg)(kg)Lurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlaceboTotal
Mean88.3 ± 13.5380.3 ± 10.8684.8 ± 21.8482 ± 16.5586.8 ± 15.286.7 ± 15.0785 ± 14.99
BMI (kg/m^2)
BMI (kg/m^2)(kg/m^2)Lurasidone 30 mgLurasidone 75 mgLurasidone 150 mgLurasidone 300 mgLurasidone 450 mgPlaceboTotal
Mean30.88 ± 6.44427.1 ± 5.52227.68 ± 5.97529.83 ± 6.49328.77 ± 5.12530.37 ± 3.91929.23 ± 5.295

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Dr. David Walling
    Long Beach, California 90806, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Mar 2019, 9 months.

Results were first posted in May 2020, 1 year 1 month after primary completion.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 9 months is close to that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2018
First posted
Aug 13, 2018
StartActual
Jun 7, 2018
Primary completionActual
Mar 29, 2019
CompletionActual
Mar 29, 2019
Results first posted
May 8, 2020
Last update
May 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03627195
Responsible party
Sponsor
First posted
Aug 13, 2018
Start date
Jun 7, 2018
Primary completion
Mar 29, 2019
Completion
Mar 29, 2019
Results posted
May 8, 2020
Last update
May 8, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion